ACE2 and COVID-19: A clinical trial proposed that the efficacy of captopril nebulization in COVID-19 patients could be tested in a randomized study and hopes that patients with SARS-CoV-2 pneumonia could inhale this medication to increase ACE2 expression while maximizing lung action and reducing side effects [23,24].